List of Fycompa drug patents

Fycompa is owned by Eisai Inc.

Fycompa contains Perampanel.

Fycompa has a total of 2 drug patents out of which 0 drug patents have expired.

Fycompa was authorised for market use on 29 April, 2016.

Fycompa is available in suspension;oral dosage forms.

Fycompa can be used as treatment of primary generalized tonic-clonic seizures as adjunctive therapy in patients with epilepsy 12 years of age and older; treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older; treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy; treatment of primary generalized tonic-clonic seizures as adjunctive therapy in patients with epilepsy; treatment of epilepsy.

The generics of Fycompa are possible to be released after 01 July, 2026.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6949571 EISAI INC 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
Jun, 2023

(4 months from now)

US8772497 EISAI INC Method for producing 1, 2-dihydropyridine-2-one compound
Jul, 2026

(3 years from now)

Drugs and Companies using PERAMPANEL ingredient

Market Authorisation Date: 29 April, 2016

Treatment: Treatment of primary generalized tonic-clonic seizures as adjunctive therapy in patients with epilepsy 12 years of age and older; Treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older; Treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy; Treatment of primary generalized tonic-clonic seizures as adjunctive therapy in patients with epilepsy; Treatment of epilepsy

Dosage: SUSPENSION;ORAL

How can I launch a generic of FYCOMPA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in